Triple Negative
Recently Published Documents


TOTAL DOCUMENTS

14531
(FIVE YEARS 10194)

H-INDEX

139
(FIVE YEARS 67)

2021 ◽  
Author(s):  
Shahan Mamoor

We mined published microarray data (1) to understand the most significant gene expression differences in the tumors of triple negative breast cancer patients based on survival following treatment: dead or alive. We observed significant transcriptome-wide differential expression of ALX homeobox 1, encoded by ALX1 when comparing the primary tumors of triple negative breast cancer patients dead or alive. Importantly, ALX1 expression was significantly correlated with distant metastasis-free survival in basal subtype breast cancer, a molecular subtype sharing significant overlap with triple negative breast cancer. ALX1 may be of relevance as a biomarker or as a molecule of interest in understanding the etiology or progression of triple negative breast cancer.


2021 ◽  
Author(s):  
Shahan Mamoor

We mined published microarray data (1) to understand the most significant gene expression differences in the tumors of triple negative breast cancer patients based on survival following treatment: dead or alive. We observed significant transcriptome-wide differential expression of ras homolog family member D, encoded by RHOD when comparing the primary tumors of triple negative breast cancer patients dead or alive. Importantly, RHOD expression was significantly correlated with overall survival in basal subtype breast cancer, a molecular subtype sharing significant overlap with triple negative breast cancer. RHOD may be of relevance as a biomarker or as a molecule of interest in understanding the etiology or progression of triple negative breast cancer.


2021 ◽  
Author(s):  
Zhenyu Li ◽  
Qingming Jiang ◽  
Dongfang Guo ◽  
Yong Cao ◽  
Yangling Peng ◽  
...  

Abstract Background: Mucinous cystadenocarcinoma of the breast is a very rare and special type adenocarcinoma of the mammary tract. We report a rare case of mucinous cystadenocarcinoma of the breast with an unfavourable prognosis which was confirmed after surgical resection pathologically. Case summary: At low power appearance, the tumor formed mucus-filled spaces of varying sizes, and with mucus-rich tumor cells lining the walls. The tumor cells were arranged in papillary structures. At high magnification, the tumor cells shown moderate to severe atypia, which were most of simple columnar cells with nuclei in the base and cytoplasm rich in mucin. In some areas, tumor cells proliferated, stratified, and clustered that protruded into the cyst cavity, or formed papillary structures with thin fibrovascular core. Immunohistochemical staining showed cytoplasm CK7 strong positive of tumor cells and cytoplasm negative of CK20, PAX-8 and CDX2, which could exclude metastatic tumors from ovary and intestine. And the tumor cells also demonstrated the basal-like characters such as negative for ER, PR, HER-2 (triple-negative), CK5/6 focal positive, EGFR positive. Besides, a triple negative breast cancer with basal-like features, lymph node, thoracic wall metastasis of mucinous cystadenocarcinoma was found. Conclusion: Mucinous cystadenocarcinoma of the breast usually have a favorable prognosis, but in this case, it happened lymph node, thoracic wall metastasis, therefore, it needs extra attention of clinical workers.


2021 ◽  
Author(s):  
Shahan Mamoor

We mined published microarray data (1) to understand the most significant gene expression differences in the tumors of triple negative breast cancer patients based on survival following treatment: dead or alive. We observed significant transcriptome-wide differential expression of retinol dehydrogenase 8 (all-trans), encoded by RDH8 when comparing the primary tumors of triple negative breast cancer patients dead or alive. Importantly, RDH8 expression was significantly correlated with distant metastasis-free survival in basal subtype breast cancer, a molecular subtype sharing significant overlap with triple negative breast cancer. RDH8 may be of relevance as a biomarker or as a molecule of interest in understanding the etiology or progression of triple negative breast cancer.


2021 ◽  
Author(s):  
Ana Tečić Vuger ◽  
Robert Šeparović ◽  
Sanda Šitić ◽  
Ljubica Vazdar ◽  
Mirjana Pavlović ◽  
...  

Abstract Aims This study aimed to investigate the association between tumor-infiltrating lymphocytes (TIL) and androgen receptors (AR) and to assess their impact on early triple-negative breast cancer (TNBC) prognosis. Previous studies analyzed only stromal TIL (sTIL) and intratumoral (ITIL), while this study includes an additional spatial analysis for TIL in central tumor (CT) and invasive margin (IM) compartments and correlation with AR expression and overall survival (OS). Methods A retrospective cohort study encompassing 152 early TNBC tissue samples from patients treated at a tertiary oncologic center between 2009 and 2012. TIL and AR were assessed using formalin-fixed paraffin-embedded samples, using hematoxylin-eosin staining and immunohistochemistry. AR-positive tumors were considered those with ≥ 1% nuclear-stained cells. Results High TIL indicators were found to be positive prognostic factors. Although AR was not an independent prognostic factor, its interactions with sTIL and ITIL at IM impacted OS. Positive AR along with high sTIL and ITIL in IM were associated with favorable OS (HR for sTIL 0.22; 95%CI 0.05–0.97; p = 0.045 and HR for ITIL 0.10; 95%CI 0.01–0.78; p = 0.028). Conclusion Spatial morphological analysis of TIL reveals an additional prognostic value when combined with AR status, and shows a clinically significant impact on OS in early TNBC.


2021 ◽  
Author(s):  
Shahan Mamoor

We mined published microarray data (1) to understand the most significant gene expression differences in the tumors of triple negative breast cancer patients based on survival following treatment: dead or alive. We observed significant transcriptome-wide differential expression of hairy and enhancer of split 1, encoded by HES1 when comparing the primary tumors of triple negative breast cancer patients dead or alive. Importantly, HES1 expression was significantly correlated with overall survival in basal subtype breast cancer, a molecular subtype sharing significant overlap with triple negative breast cancer. HES1 may be of relevance as a biomarker or as a molecule of interest in understanding the etiology or progression of triple negative breast cancer.


2021 ◽  
Author(s):  
Shahan Mamoor

We mined published microarray data (1) to understand the most significant gene expression differences in the tumors of triple negative breast cancer patients based on survival following treatment: dead or alive. We observed significant transcriptome-wide differential expression of programmed cell death 1 ligand 2, encoded by PDCD1LG2, also known as PD-L2, when comparing the primary tumors of triple negative breast cancer patients dead or alive. Importantly, PD-L2 expression was significantly correlated with overall survival in basal subtype breast cancer, a molecular subtype sharing significant overlap with triple negative breast cancer. PD-L2 may be of relevance as a biomarker or as a molecule of interest in understanding the etiology or progression of triple negative breast cancer.


2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Dora Hammerl ◽  
John W. M. Martens ◽  
Mieke Timmermans ◽  
Marcel Smid ◽  
Anita M. Trapman-Jansen ◽  
...  

AbstractOnly a subgroup of triple-negative breast cancer (TNBC) responds to immune checkpoint inhibitors (ICI). To better understand lack of response to ICI, we analyze 681 TNBCs for spatial immune cell contextures in relation to clinical outcomes and pathways of T cell evasion. Excluded, ignored and inflamed phenotypes can be captured by a gene classifier that predicts prognosis of various cancers as well as anti-PD1 response of metastatic TNBC patients in a phase II trial. The excluded phenotype, which is associated with resistance to anti-PD1, demonstrates deposits of collagen-10, enhanced glycolysis, and activation of TGFβ/VEGF pathways; the ignored phenotype, also associated with resistance to anti-PD1, shows either high density of CD163+ myeloid cells or activation of WNT/PPARγ pathways; whereas the inflamed phenotype, which is associated with response to anti-PD1, revealed necrosis, high density of CLEC9A+ dendritic cells, high TCR clonality independent of neo-antigens, and enhanced expression of T cell co-inhibitory receptors.


2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Hazem Ghebeh ◽  
Adher Al-Sayed ◽  
Riham Eiada ◽  
Leilani Cabangon ◽  
Dahish Ajarim ◽  
...  

AbstractTherapeutic anti-PD-L1 antibodies are safe as a monotherapy, albeit with minimal efficacy in triple-negative breast cancer (TNBC). This trial aimed to test the safety and efficacy of Durvalumab and Paclitaxel in metastatic TNBC. In this open-label, one-arm trial, five cycles of weekly paclitaxel were delivered intravenously (IV) concurrent with Durvalumab that was given IV every 2 weeks. The combination was preceded by one cycle of paclitaxel alone, for immunological priming, followed by Durvalumab solo until disease progression or unacceptable toxicity. Between 2017 and 2019, 14 patients received at least one cycle of the combination therapy. The therapy was safe with no-dose limiting toxicity, except one case of skin lesions. Adverse events (AEs) were reported in 71% of patients, and there was no death due to the combination therapy. Regardless of grade, the most common AEs were headache and peripheral neuropathy, as each happened in four patients (29%), followed by fatigue and skin rash in three patients (21%) each. Grade 3/4 AEs were experienced by three patients (21%), with the most common being headache and anemia, which happened in two patients (14%). The confirmed objective response rate (ORR) was observed in five patients with a median duration of 10.0 months. Median Progression-free survival (PFS) and overall survival (OS) were 5 and 20.7 months, respectively. The combination of Durvalumab and Paclitaxel is safe, leaving room for additional agents. This is the first report on the combination of Durvalumab and Paclitaxel in the treatment of TNBC (NCT02628132).


Sign in / Sign up

Export Citation Format

Share Document